Signaturefd LLC Has $1.05 Million Stock Position in Unum Group (NYSE:UNM)

Signaturefd LLC lessened its stake in shares of Unum Group (NYSE:UNM) by 2.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,136 shares of the financial services provider’s stock after selling 687 shares during the quarter. Signaturefd LLC’s holdings in Unum Group were worth $1,046,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in UNM. Silver Oak Securities Incorporated acquired a new stake in Unum Group in the third quarter valued at approximately $25,000. Contravisory Investment Management Inc. acquired a new stake in Unum Group in the 4th quarter valued at $25,000. Bangor Savings Bank increased its stake in Unum Group by 100.0% during the 3rd quarter. Bangor Savings Bank now owns 664 shares of the financial services provider’s stock valued at $33,000 after purchasing an additional 332 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Unum Group during the third quarter worth $36,000. Finally, Daiwa Securities Group Inc. bought a new position in shares of Unum Group in the fourth quarter valued at $36,000. 86.57% of the stock is currently owned by institutional investors and hedge funds.

Unum Group Trading Up 0.8 %

Shares of Unum Group stock opened at $51.79 on Tuesday. The stock has a fifty day moving average price of $51.03 and a 200-day moving average price of $47.59. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.27 and a quick ratio of 0.27. The firm has a market cap of $9.94 billion, a PE ratio of 7.98, a P/E/G ratio of 1.03 and a beta of 0.87. Unum Group has a 1 year low of $40.04 and a 1 year high of $54.57.

Unum Group (NYSE:UNM) last posted its quarterly earnings data on Tuesday, January 30th. The financial services provider reported $1.79 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.07). The company had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Unum Group had a return on equity of 16.03% and a net margin of 10.36%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the business posted $1.43 EPS. Equities research analysts anticipate that Unum Group will post 8.18 EPS for the current year.

Unum Group Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 17th. Investors of record on Friday, April 26th will be paid a $0.365 dividend. The ex-dividend date of this dividend is Thursday, April 25th. This represents a $1.46 annualized dividend and a yield of 2.82%. Unum Group’s payout ratio is 22.50%.

Insider Buying and Selling at Unum Group

In other news, CEO Richard P. Mckenney sold 50,000 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $49.15, for a total transaction of $2,457,500.00. Following the transaction, the chief executive officer now owns 1,076,753 shares of the company’s stock, valued at approximately $52,922,409.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Richard P. Mckenney sold 50,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $49.15, for a total value of $2,457,500.00. Following the sale, the chief executive officer now directly owns 1,076,753 shares in the company, valued at approximately $52,922,409.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Steven Andrew Zabel sold 10,000 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $51.06, for a total transaction of $510,600.00. Following the sale, the chief financial officer now directly owns 122,246 shares in the company, valued at $6,241,880.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,000 shares of company stock valued at $4,018,100. Company insiders own 0.93% of the company’s stock.

Analyst Ratings Changes

UNM has been the topic of a number of analyst reports. StockNews.com upgraded shares of Unum Group from a “hold” rating to a “buy” rating in a report on Wednesday, January 31st. Morgan Stanley raised their target price on Unum Group from $50.00 to $52.00 and gave the company an “equal weight” rating in a report on Monday, April 15th. The Goldman Sachs Group lifted their target price on Unum Group from $47.00 to $52.00 and gave the company a “neutral” rating in a research report on Wednesday, January 31st. Wells Fargo & Company raised their price objective on Unum Group from $64.00 to $66.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. Finally, JPMorgan Chase & Co. upped their target price on shares of Unum Group from $56.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $56.38.

Unum Group Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.